JP2021508255A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021508255A5 JP2021508255A5 JP2020554353A JP2020554353A JP2021508255A5 JP 2021508255 A5 JP2021508255 A5 JP 2021508255A5 JP 2020554353 A JP2020554353 A JP 2020554353A JP 2020554353 A JP2020554353 A JP 2020554353A JP 2021508255 A5 JP2021508255 A5 JP 2021508255A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- antibody
- cancer
- fold
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229960005386 ipilimumab Drugs 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 4
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000005975 antitumor immune response Effects 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 229960000106 biosimilars Drugs 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- -1 coatings Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000007951 isotonicity adjuster Substances 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022093122A JP7464300B2 (ja) | 2017-12-20 | 2022-06-08 | Ｃｔｌａ－４に結合する抗体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607917P | 2017-12-20 | 2017-12-20 | |
| US62/607,917 | 2017-12-20 | ||
| PCT/CN2018/122190 WO2019120232A1 (en) | 2017-12-20 | 2018-12-19 | Antibodies binding ctla-4 and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022093122A Division JP7464300B2 (ja) | 2017-12-20 | 2022-06-08 | Ｃｔｌａ－４に結合する抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021508255A JP2021508255A (ja) | 2021-03-04 |
| JP2021508255A5 true JP2021508255A5 (https=) | 2021-08-05 |
| JP7087107B2 JP7087107B2 (ja) | 2022-06-20 |
Family
ID=66994401
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020554353A Active JP7087107B2 (ja) | 2017-12-20 | 2018-12-19 | Ｃｔｌａ－４に結合する抗体およびその使用 |
| JP2022093122A Active JP7464300B2 (ja) | 2017-12-20 | 2022-06-08 | Ｃｔｌａ－４に結合する抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022093122A Active JP7464300B2 (ja) | 2017-12-20 | 2022-06-08 | Ｃｔｌａ－４に結合する抗体およびその使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11098122B2 (https=) |
| EP (2) | EP3710484B1 (https=) |
| JP (2) | JP7087107B2 (https=) |
| KR (1) | KR102476887B1 (https=) |
| CN (2) | CN114409786B (https=) |
| AU (1) | AU2018391831B2 (https=) |
| BR (1) | BR112020012364A2 (https=) |
| CA (1) | CA3085861C (https=) |
| DK (1) | DK3710484T5 (https=) |
| ES (1) | ES2965187T3 (https=) |
| FI (1) | FI3710484T3 (https=) |
| IL (1) | IL275391B2 (https=) |
| MX (1) | MX2020006585A (https=) |
| PH (1) | PH12020550933A1 (https=) |
| PL (1) | PL3710484T3 (https=) |
| RU (1) | RU2756100C1 (https=) |
| SG (1) | SG11202005692WA (https=) |
| WO (1) | WO2019120232A1 (https=) |
| ZA (1) | ZA202003641B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020012364A2 (pt) * | 2017-12-20 | 2020-11-24 | Harbour Biomed (Shanghai) Co., Ltd | anticorpos de ligação a ctla-4 e usos dos mesmos |
| CN113614109A (zh) | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | 双功能抗pd-1/il-7分子 |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| CN114729045B (zh) * | 2019-09-26 | 2025-09-09 | 斯特库比公司 | 对糖基化的ctla-4特异性的抗体及其使用方法 |
| AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Bifunctional molecules comprising an IL-7 variant |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| CN112569183B (zh) * | 2020-12-11 | 2022-12-09 | 上海赛金生物医药有限公司 | 一种抗ctla-4抗体及融合蛋白的制剂 |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| AU2022253351A1 (en) | 2021-04-09 | 2023-10-12 | Boehringer Ingelheim International Gmbh | New scaffold for bifunctional molecules with improved properties |
| WO2022222961A1 (zh) * | 2021-04-21 | 2022-10-27 | 和铂医药(上海)有限责任公司 | 结合ctla-4的抗体及其用途 |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| EP4582453A1 (en) * | 2022-09-02 | 2025-07-09 | Cichlid Inc. | Anti-ctla-4 monoclonal antibody and use thereof |
| CN121358499A (zh) | 2023-03-30 | 2026-01-16 | Ose免疫疗法 | 靶向活化的免疫细胞以表达免疫细胞增强分子的基于脂质的纳米粒及其用途 |
| AU2024254671A1 (en) | 2023-03-30 | 2025-10-02 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE54046B1 (en) | 1981-08-25 | 1989-05-24 | Celltech Ltd | Expression vectors |
| US4579821A (en) | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US4486533A (en) | 1982-09-02 | 1984-12-04 | St. Louis University | Filamentous fungi functional replicating extrachromosomal element |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4599311A (en) | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
| US4977092A (en) | 1985-06-26 | 1990-12-11 | Amgen | Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US4661454A (en) | 1983-02-28 | 1987-04-28 | Collaborative Research, Inc. | GAL1 yeast promoter linked to non galactokinase gene |
| US5139936A (en) | 1983-02-28 | 1992-08-18 | Collaborative Research, Inc. | Use of the GAL1 yeast promoter |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4870008A (en) | 1983-08-12 | 1989-09-26 | Chiron Corporation | Secretory expression in eukaryotes |
| US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
| US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
| US4990446A (en) | 1984-12-06 | 1991-02-05 | Labofina, S.A. | Promoters for the expression of foreign genes in yeast, plasmids comprising them, and use thereof for the production of polypeptides |
| GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4882279A (en) | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
| US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US5063154A (en) | 1987-06-24 | 1991-11-05 | Whitehead Institute For Biomedical Research | Pheromone - inducible yeast promoter |
| US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5162228A (en) | 1988-12-28 | 1992-11-10 | Takeda Chemical Industries, Ltd. | Gylceraldehyde-3-phosphate dehydrogenase gene and promoter |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5162222A (en) | 1989-07-07 | 1992-11-10 | Guarino Linda A | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5298418A (en) | 1991-09-16 | 1994-03-29 | Boyce Thompson Institute For Plant Research, Inc. | Cell line isolated from larval midgut tissue of Trichoplusia ni |
| WO1994006463A1 (en) | 1992-09-14 | 1994-03-31 | Pfizer Inc | Immortalized cells and uses therefor |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| US5716808A (en) | 1995-11-09 | 1998-02-10 | Zymogenetics, Inc. | Genetic engineering of pichia methanolica |
| US5955349A (en) | 1996-08-26 | 1999-09-21 | Zymogenetics, Inc. | Compositions and methods for producing heterologous polypeptides in Pichia methanolica |
| US5854039A (en) | 1996-07-17 | 1998-12-29 | Zymogenetics, Inc. | Transformation of pichia methanolica |
| US5736383A (en) | 1996-08-26 | 1998-04-07 | Zymogenetics, Inc. | Preparation of Pichia methanolica auxotrophic mutants |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| DK1141028T3 (da) * | 1998-12-23 | 2010-05-25 | Pfizer | Humane monoklonale antistoffer til CTLA-4 |
| IL148079A0 (en) * | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| EP1261376A1 (en) * | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| PT1391464E (pt) * | 2001-04-27 | 2007-11-15 | Kirin Pharma Kk | Anticorpo monoclonal anti-cd40 |
| EP1732600A2 (en) * | 2004-03-26 | 2006-12-20 | Pfizer Products Incorporated | Uses of anti-ctla-4 antibodies |
| SI2311874T1 (sl) | 2004-07-22 | 2017-12-29 | Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics | Vezavne molekule |
| US20060240006A1 (en) | 2005-04-20 | 2006-10-26 | Chishih Chu | Novel antibody structures derived from human germline sequences |
| KR20090088891A (ko) * | 2006-11-15 | 2009-08-20 | 메다렉스, 인코포레이티드 | 비티엘에이에 대한 인간 단일클론 항체 및 이용 방법 |
| GB0903325D0 (en) * | 2009-02-26 | 2009-04-08 | Univ Aberdeen | Antibody molecules |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| KR101535341B1 (ko) * | 2012-07-02 | 2015-07-13 | 한화케미칼 주식회사 | Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 |
| CN104292334B (zh) * | 2014-04-25 | 2018-11-27 | 河南省健康伟业生物医药研究股份有限公司 | 一种全人源抗ctla-4单克隆抗体、制备方法及应用 |
| CN108271359B (zh) * | 2015-02-13 | 2021-11-09 | 索伦托药业有限公司 | 结合ctla4的抗体治疗剂 |
| CN106046165B (zh) | 2015-07-20 | 2019-05-21 | 广西医科大学 | 抗CTLA-4的纳米抗体Nb30及其制备方法与应用 |
| CN106046164B (zh) * | 2015-07-20 | 2019-10-25 | 广西医科大学 | 抗CTLA-4的纳米抗体Nb36及其制备方法与应用 |
| CN106188297B (zh) | 2015-07-20 | 2019-09-27 | 广西医科大学 | 抗CTLA-4的纳米抗体Nb91及其制备方法与应用 |
| CN106220732B (zh) | 2015-07-20 | 2019-05-21 | 广西医科大学 | 抗CTLA-4的纳米抗体Nb16及其制备方法与应用 |
| CN107400166A (zh) * | 2016-05-19 | 2017-11-28 | 苏州康宁杰瑞生物科技有限公司 | 针对ctla4的单域抗体及其衍生蛋白 |
| BR112020012364A2 (pt) * | 2017-12-20 | 2020-11-24 | Harbour Biomed (Shanghai) Co., Ltd | anticorpos de ligação a ctla-4 e usos dos mesmos |
-
2018
- 2018-12-19 BR BR112020012364-1A patent/BR112020012364A2/pt unknown
- 2018-12-19 CA CA3085861A patent/CA3085861C/en active Active
- 2018-12-19 WO PCT/CN2018/122190 patent/WO2019120232A1/en not_active Ceased
- 2018-12-19 JP JP2020554353A patent/JP7087107B2/ja active Active
- 2018-12-19 ES ES18892518T patent/ES2965187T3/es active Active
- 2018-12-19 US US16/224,825 patent/US11098122B2/en active Active
- 2018-12-19 IL IL275391A patent/IL275391B2/en unknown
- 2018-12-19 KR KR1020207020932A patent/KR102476887B1/ko active Active
- 2018-12-19 SG SG11202005692WA patent/SG11202005692WA/en unknown
- 2018-12-19 EP EP18892518.4A patent/EP3710484B1/en active Active
- 2018-12-19 AU AU2018391831A patent/AU2018391831B2/en active Active
- 2018-12-19 EP EP23205205.0A patent/EP4295915A3/en active Pending
- 2018-12-19 RU RU2020123859A patent/RU2756100C1/ru active
- 2018-12-19 CN CN202210126917.0A patent/CN114409786B/zh active Active
- 2018-12-19 CN CN201880083036.7A patent/CN111655728B/zh active Active
- 2018-12-19 PL PL18892518.4T patent/PL3710484T3/pl unknown
- 2018-12-19 FI FIEP18892518.4T patent/FI3710484T3/fi active
- 2018-12-19 DK DK18892518.4T patent/DK3710484T5/da active
- 2018-12-19 MX MX2020006585A patent/MX2020006585A/es unknown
-
2020
- 2020-06-17 ZA ZA2020/03641A patent/ZA202003641B/en unknown
- 2020-06-18 PH PH12020550933A patent/PH12020550933A1/en unknown
-
2021
- 2021-07-14 US US17/375,940 patent/US12240905B2/en active Active
-
2022
- 2022-06-08 JP JP2022093122A patent/JP7464300B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021508255A5 (https=) | ||
| IL275391B2 (en) | Antibodies binding ctla-4 and uses thereof | |
| JP2019532625A5 (https=) | ||
| JP2020127426A5 (https=) | ||
| JP2020528750A5 (https=) | ||
| JP2023113893A5 (https=) | ||
| JP2020510422A5 (https=) | ||
| JP2020503001A5 (https=) | ||
| RU2017119428A (ru) | Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit | |
| FI3946621T3 (fi) | Mage a4 -t-solureptoreja | |
| JP2015535691A5 (https=) | ||
| JP2017534633A5 (https=) | ||
| EP4282877A3 (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
| RU2017118225A (ru) | Антитела к PD-1 и способы их применения | |
| JP2020531043A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| JP2020500523A5 (https=) | ||
| JP2016525117A5 (https=) | ||
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| JP2017506067A5 (https=) | ||
| JP2015527070A5 (https=) | ||
| JP2018503365A5 (https=) | ||
| ME02369B (me) | Antitela za terapiju kancera koji eksprimira klaudin 6 | |
| RU2018105963A (ru) | Антитело против глипикана-3 и его применение | |
| JP2015517470A5 (https=) |